"IMU has now released results from the Phase 1b Gastric Cancer...

"IMU has now released results from the Phase 1b Gastric Cancer trial, showing that all dose levels of its HER-Vaxx cancer vaccine showed an increase in antibodies in patients.

The preliminary topline results are even more impressive...

Of the 10 patients evaluable for tumour growth assessment during the study, 4 showed stable disease (SD), and a further 5 showed partial response (PR) for their best overall response.
A partial tumour response means a reduction in the total tumour burden by greater than 30%. A stable disease response means the total tumour burden either increases less than 20% or decreases less than 30%.

Note that this means an impressive 9 out of the 10 patients responded to the treatment — which is excellent going for a Phase 1b clinical asset like HER-Vaxx.

With the full results now in for the Phase 1b trial, IMU has entered advanced preparations stage for the Phase 2 study to start early in 2019.

...

There’s one further consideration working in IMU’s favour as well: Big Pharma is on the hunt for novel combinations of drugs, where traditional treatments are combined with immunotherapy, which can work together to increase patient response rates without the threats of higher toxicity or prohibitive costs...
With Phase 2 set to kick off early next year, IMU could well be on the home stretch to a lucrative deal."